ASDA Partners With Avery Berkel and Hanshow to Enhance UK Sustainability and Supermarket Shopping Experience
25.7.2023 11:00:00 EEST | Business Wire | Press release
ASDA, in partnership with Avery Berkel and Hanshow, has launched a strategic project to create the first sustainability trial store in the UK that utilizes leading ESL technology and digital retail solutions to enhance operations and improve the shopping experience for customers. This partnership aims to promote refillable solutions for supermarket shopping in the UK, with a focus on sustainability and customer experience. Avery Berkel and Hanshow collaborated to leverage their expertise in retail scales, enterprise scale management, and electronic shelf labels (ESLs) to develop a sustainable solution for the Middleton store, eliminating the need for physical labels and creating a zero-waste solution for ASDA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713235215/en/
Avery Berkel and Hanshow's solutions installed in ASDA (Photo: Business Wire)
The solutions offered by Avery Berkel and Hanshow allow ASDA to carry out its commitment to zero-waste shopping through its bring-your-own-container solution and promoting its ‘Refill Price Promise’ program, which guarantees lower prices to help customers shop more sustainably. ESL technology reduces the cost and time of manual updates, while allowing ASDA to make real-time changes to prices and promotions. It also allows customers to see price differences in wrapped and unwrapped versions of the same product. The solutions make it easier for customers to shop sustainably and are part of a greater effort to make ASDA’s refill areas more efficient and green.
Avery Berkel and Hanshow’s ESL technology streamlines in-store change administration and management, ensuring real-time price and product updates to keep shelves up to date and compliant with regulations. This flexibility to adjust prices and promotions enables retailers to respond promptly to market trends and customer demands, while reducing costs associated with label stock holding and consumables. Increased productivity and efficiency allow employees to focus on providing better customer service.
Customizability is another key feature of the ESL technology innovations, enabling ASDA and other retailers to incorporate custom fonts, images, logos, and graphics into the labels. This allows for brand alignment and a consistent visual identity across stores. The on-screen barcodes and QR codes facilitate easy scanning, streamlining checkout processes and enhancing operational efficiency.
The components of Avery Berkel and Hanshow’s solution are seamlessly integrated to provide shoppers with an enriching refill experience while emphasizing sustainability. Unlike standard printed shelf and product labels, the total refill solution offers additional product information such as refill instructions, ingredients, allergens, and storage details, encouraging sustainability in ASDA stores.
Avery Berkel and Hanshow aimed to revolutionize the shopping experience by making sustainable choices more accessible and engaging for customers. The shopper interface, designed to be simple and intuitive, ensures that even customers unfamiliar with this technology can easily navigate and participate. The collaboration among ASDA, Avery Berkel and Hanshow has led to a total solution that not only benefits the retail industry and its customers, but also provides a green solution and encourages more environmentally friendly retail practices and shopping habits. Consumer demand for sustainable retail will continue to grow in the future. Hanshow will strive to provide the sustainable retail solutions by continuously innovating and improving their digital labelling technology to meet the changing needs of customers and reduce environmental impact.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230713235215/en/
Contact information
Zishan Cai
zishan.cai@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom